KCNA3 and rheumatoid arthritis: In 2008, a company, Solvay Pharmaceuticals, filed a patent for oxazolidinediones-spiro-azepene as a novel blocker of Kv1.3 potassium channels for the treatment of T-cell-regulated autoimmune diseases such as RA (Wulff, 2010).